Effects and risk factors of TAS-102 in real-world patients with metastatic colorectal cancer, EROTAS-R study

Naohisa Yoshida,Yoshiaki Kuriu,Jun Ikeda,Michihiro Kudou,Toshihiko Kirishima,Tetsuya Okayama, Koji Miyagawa,Tsuyoshi Takagi,Masayoshi Nakanishi,Toshifumi Doi,Takeshi Ishikawa,Yoshito Itoh,Eigo Otsuji

International Journal of Clinical Oncology（2023）

引用 0|浏览7

暂无评分

摘要

Trifluridine/tipiracil (TAS-102) is an anticancer drug for metastatic colorectal cancer (CRC). This study aimed to analyze the effects and risk factors about effects of TAS-102 in real-world patients with metastatic CRC (the EROTAS-R study). This study retrospectively analyzed 271 patients aged ≥ 20 years who underwent TAS-102 for metastatic CRC at nine related institutions from 2014 to 2021. Therapeutic results of TAS-102 + bevacizumab (Bev) and TAS-102, effect predictors, adverse events (AE), and AE predictors were examined. The backgrounds of all cases were as follows: average age, 66.7 ± 10.9 years; male ratio, 59.5

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要